{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:09:58Z","timestamp":1791202198256,"version":"4.2.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5,15]]},"abstract":"<jats:p>Deletions and\/or mutations of p53 are relatively rare and late events in the natural history of B-cell chronic lymphocytic leukemia (B-CLL). However, it is unknown whether p53 signaling is functional in B-CLL and if targeted nongenotoxic activation of the p53 pathway by using nutlin-3, a small molecule inhibitor of the p53\/MDM2 interaction, is sufficient to kill B-CLL cells. In vitro treatment with nutlin-3 induced a significant cytotoxicity on primary CD19+ B-CLL cells, but not on normal CD19+ B lymphocytes, peripheral-blood mononuclear cells, or bone marrow hematopoietic progenitors. Among 29 B-CLL samples examined, only one was resistant to nutlin-3\u2013mediated cytotoxicity. The induction of p53 by nutlin-3 in B-CLL samples was accompanied by alterations of the mitochondrial potential and activation of the caspase-dependent apoptotic pathway. Among several genes related to the p53 pathway, nutlin-3 up-regulated the steady-state mRNA levels of PCNA, CDKN1A\/p21, GDF15, TNFRSF10B\/TRAIL-R2, TP53I3\/PIG3, and GADD45. This profile of gene activation showed a partial overlapping with that induced by the genotoxic drug fludarabine. Moreover, nutlin-3 synergized with both fludarabine and chlorambucil in inducing B-CLL apoptosis. Our data strongly suggest that nutlin-3 should be further investigated for clinical applications in the treatment of B-CLL.<\/jats:p>","DOI":"10.1182\/blood-2005-11-4465","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T02:03:31Z","timestamp":1138327411000},"page":"4122-4129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":123,"title":["Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)"],"prefix":"10.1182","volume":"107","author":[{"given":"Paola","family":"Secchiero","sequence":"first","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbarotto","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Zerbinati","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"di Iasio","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Gonelli","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Campioni","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Zauli","sequence":"additional","affiliation":[{"name":"From the Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, and the Department of Biomedical Sciences and Advanced Therapies, Section of Hematology, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; the Department of Medical and Morphological Researches, Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy; and the Department of Normal Human Morphology, University of Trieste, Trieste, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111904465529000_REF1","doi-asserted-by":"crossref","unstructured":"Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408: 307-310.","DOI":"10.1038\/35042675"},{"key":"2019111904465529000_REF2","doi-asserted-by":"crossref","unstructured":"Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003; 13: 49-58.","DOI":"10.1016\/S1044-579X(02)00099-8"},{"key":"2019111904465529000_REF3","doi-asserted-by":"crossref","unstructured":"Gostissa M, Hofmann TG, Will H, Del Sal G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol. 2003;15: 351-357.","DOI":"10.1016\/S0955-0674(03)00038-3"},{"key":"2019111904465529000_REF4","doi-asserted-by":"crossref","unstructured":"Stommel JM, Wahl GM. Accelerated MDM2 autodegradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23: 1547-1556.","DOI":"10.1038\/sj.emboj.7600145"},{"key":"2019111904465529000_REF5","doi-asserted-by":"crossref","unstructured":"Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303: 844-848.","DOI":"10.1126\/science.1092472"},{"key":"2019111904465529000_REF6","doi-asserted-by":"crossref","unstructured":"Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65: 1918-1924.","DOI":"10.1158\/0008-5472.CAN-04-3576"},{"key":"2019111904465529000_REF7","doi-asserted-by":"crossref","unstructured":"Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low grade B-cell malignancies using biological response modifiers. Semin Oncol. 2002;29: 10-24.","DOI":"10.1053\/sonc.2002.30155"},{"key":"2019111904465529000_REF8","doi-asserted-by":"crossref","unstructured":"Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1799-1801.","DOI":"10.1056\/NEJM200012143432410"},{"key":"2019111904465529000_REF9","doi-asserted-by":"crossref","unstructured":"Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85: 1580-1589.","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580"},{"key":"2019111904465529000_REF10","unstructured":"Cuneo A, Bigoni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders: clinicobiological significance. Haematologica. 2002;87: 44-51."},{"key":"2019111904465529000_REF11","doi-asserted-by":"crossref","unstructured":"Zauli G, Re MC, Furlini G, et al. Human immundeficiency virus type-1 envelope glycoprotein GP120-mediated killing of human hematopoietic progenitors (CD34+ cells). J Gen Virol. 1992;73: 417-421.","DOI":"10.1099\/0022-1317-73-2-417"},{"key":"2019111904465529000_REF12","unstructured":"SuperArray Bioscience Corporation. Gene list. OHS-802; http:\/\/www.superarray.com\/gene_array_product\/HTML\/OHS-802.html. Accessed May 2, 2004."},{"key":"2019111904465529000_REF13","unstructured":"SuperArray Bioscience Corporation. Gene list. HS-603; http:\/\/www.superarray.com\/gene_array_product\/HTML\/HS-603.html. Accessed May 2, 2004."},{"key":"2019111904465529000_REF14","doi-asserted-by":"crossref","unstructured":"Chou T, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22: 27-55.","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"2019111904465529000_REF15","doi-asserted-by":"crossref","unstructured":"Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1910-1916.","DOI":"10.1056\/NEJM200012283432602"},{"key":"2019111904465529000_REF16","doi-asserted-by":"crossref","unstructured":"Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100: 1410-1416.","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"2019111904465529000_REF17","unstructured":"Rossi D, Capello D, Gloghini A, et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004;89: 154-164."},{"key":"2019111904465529000_REF18","doi-asserted-by":"crossref","unstructured":"Valganon M, Giraldo P, Agirre X, et al. p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III\/IV. Br J Haematol. 2005;129: 53-59.","DOI":"10.1111\/j.1365-2141.2005.05405.x"},{"key":"2019111904465529000_REF19","doi-asserted-by":"crossref","unstructured":"Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82: 2617-2623.","DOI":"10.1182\/blood.V82.9.2617.2617"},{"key":"2019111904465529000_REF20","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194: 1639-1647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2019111904465529000_REF21","doi-asserted-by":"crossref","unstructured":"Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98: 814-822.","DOI":"10.1182\/blood.V98.3.814"},{"key":"2019111904465529000_REF22","doi-asserted-by":"crossref","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1750-1757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"2019111904465529000_REF23","doi-asserted-by":"crossref","unstructured":"Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98: 2319-2325.","DOI":"10.1182\/blood.V98.8.2319"},{"key":"2019111904465529000_REF24","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 2004;104: 1428-1434.","DOI":"10.1182\/blood-2003-09-3236"},{"key":"2019111904465529000_REF25","doi-asserted-by":"crossref","unstructured":"Pettitt AR, Clarke AR, Cawley JC, Griffiths SD. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol. 1999;105: 986-988.","DOI":"10.1046\/j.1365-2141.1999.01448.x"},{"key":"2019111904465529000_REF26","doi-asserted-by":"crossref","unstructured":"Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2: 594-604.","DOI":"10.1038\/nrc864"},{"key":"2019111904465529000_REF27","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348: 1764-1775.","DOI":"10.1056\/NEJMoa023143"},{"key":"2019111904465529000_REF28","doi-asserted-by":"crossref","unstructured":"Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101: 4944-4951.","DOI":"10.1182\/blood-2002-10-3306"},{"key":"2019111904465529000_REF29","doi-asserted-by":"crossref","unstructured":"Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106: 3150-3159.","DOI":"10.1182\/blood-2005-02-0553"},{"key":"2019111904465529000_REF30","doi-asserted-by":"crossref","unstructured":"Stu\u0308hmer T, Chatterjee M, Hildebrandt M, et al. Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106: 3609-3617.","DOI":"10.1182\/blood-2005-04-1489"},{"key":"2019111904465529000_REF31","doi-asserted-by":"crossref","unstructured":"Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem. 1998;273: 33048-33053.","DOI":"10.1074\/jbc.273.49.33048"},{"key":"2019111904465529000_REF32","doi-asserted-by":"crossref","unstructured":"Dumaz N, Meek DW. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 1999;18: 7002-7010.","DOI":"10.1093\/emboj\/18.24.7002"},{"key":"2019111904465529000_REF33","doi-asserted-by":"crossref","unstructured":"Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999;19: 1751-1758.","DOI":"10.1128\/MCB.19.3.1751"},{"key":"2019111904465529000_","doi-asserted-by":"crossref","unstructured":"Wu Z, Earle J, Saito S, Anderson CW, Appella E, Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol. 2002;22: 2441-2449.","DOI":"10.1128\/MCB.22.8.2441-2449.2002"},{"key":"2019111904465529000_REF35","doi-asserted-by":"crossref","unstructured":"Chao C, Hergenhahn M, Kaeser MD, et al. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 response. J Biol Chem. 2003;278: 41028-41033.","DOI":"10.1074\/jbc.M306938200"},{"key":"2019111904465529000_REF36","doi-asserted-by":"crossref","unstructured":"Thompson T, Tovar C, Yang H. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem. 2004;279: 53015-53022.","DOI":"10.1074\/jbc.M410233200"},{"key":"2019111904465529000_REF37","doi-asserted-by":"crossref","unstructured":"Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100: 3741-3748.","DOI":"10.1182\/blood-2002-02-0539"},{"key":"2019111904465529000_REF38","doi-asserted-by":"crossref","unstructured":"el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8: 345-357.","DOI":"10.1006\/scbi.1998.0097"},{"key":"2019111904465529000_REF39","doi-asserted-by":"crossref","unstructured":"Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11: 577-590.","DOI":"10.1016\/S1097-2765(03)00050-9"},{"key":"2019111904465529000_REF40","doi-asserted-by":"crossref","unstructured":"Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005; 280: 19166-19176.","DOI":"10.1074\/jbc.M410691200"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/10\/4122\/466186\/zh801006004122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/10\/4122\/466186\/zh801006004122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T09:47:15Z","timestamp":1574156835000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/10\/4122\/109795\/Functional-integrity-of-the-p53mediated-apoptotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,15]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-11-4465","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,15]]}}}